Search Within

Andrew L. Laccetti

Formats
  1. Meeting Abstract (21)
  2. Journal Article (4)
  3. Review (1)
Groups
  1. Genitourinary Oncology Service (26)
  2. Solid Tumor Oncology Division (26)
  3. Department of Medicine (16)
  4. Hematologic Malignancies, Division of (8)
  5. Weinberg Fellows (8)
  6. Radiology, Department of (7)

More Groups

People
  1. David Aggen (8)
  2. Deaglan McHugh (7)
  3. Neil Shah (7)
  4. Ritesh Kotecha (7)
  5. Chung-Han Lee (6)
  6. Jonathan Rosenberg (6)

More People

Years
  1. 2025 (3)
  2. 2024 (7)
  3. 2023 (9)
  4. 2022 (1)
  5. 2021 (3)
  6. 2020 (3)
Publications
  1. Journal of Clinical Oncology (18)
  2. Annals of Oncology (3)
  3. Cancer Medicine (1)
  4. Clinical Nuclear Medicine (1)
  5. European Urology (1)
  6. OncoTargets and Therapy (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (18)
  2. Oxford University Press (3)
  3. Dove Medical Press Ltd (1)
  4. Elsevier Inc. (1)
  5. Elsevier Science, Inc. (1)
  6. Lippincott Williams & Wilkins (1)

More Publishers

Results (26)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial
    Meeting Abstract

    Lee, C. H.; Voss, M. H.; Carlo, M. I.; Chen, Y. B.; Reznik, E.; Knezevic, A.; Lefkowitz, R. A.; Shapnik, N.; Tassone, D.; Dadoun, C.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Enfortumab vedotin in FGFR3-mutated advanced urothelial carcinoma
    Meeting Abstract

    Teo, M. Y.; Ratna, N.; Regazzi, A. M.; Zimmerman, D. E.; McHugh, D. J.; Laccetti, A. L.; Xiao, H.; Lee, C. H.; Aggen, D. H.; Funt, S. A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes
    Journal Article

    Laccetti, A. L.; Garmezy, B.; Xiao, L.; Economides, M.; Venkatesan, A.; Gao, J.; Jonasch, E.; Corn, P.; Zurita-Saavedra, A.; Brown, L. C.; more...
    Cancer Medicine (2021)

    Fulltext@MSK | Save
  • Technology-enabled longitudinal monitoring of patient-reported outcomes (PROs) to individualize care of immune-related adverse events (irAEs) in patients (pts) treated with immune checkpoint inhibitors (ICIs)
    Meeting Abstract

    Msaouel, P.; Van Alstine, M. L.; Oromendia, C.; Gao, J.; Wang, Y.; Siddiqui, B. A.; Siefker-Radtke, A. O.; Shah, A. Y.; Shaw, L.; Lopez, L.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Combination therapy with nivolumab and tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma
    Meeting Abstract

    Garmezy, B.; Zhang, T.; Laccetti, A. L.; Economides, M. P.; Shah, A. Y.; Tannir, N. M.; Jonasch, E.; Msaouel, P.; Zurita, A. J.; Corn, P. G.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A clinical evaluation of enzalutamide in metastatic castration-sensitive prostate cancer: Guiding principles for treatment selection and perspectives on research
    Review

    Laccetti, A. L.; Morris, M. J.; Kantoff, P. W.
    OncoTargets and Therapy (2020)

    Fulltext@MSK | Save